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Abstract
Background: Promoting well-being and preventing poor mental health in young people is a major global priority.
Building emotional competence (EC) skills via a mobile app may be an effective, scalable and acceptable way to do
this. However, few large-scale controlled trials have examined the efficacy of mobile apps in promoting mental
health in young people; none have tailored the app to individual profiles.
Method/design: The Emotional Competence for Well-Being in Young Adults cohort multiple randomised
controlled trial (cmRCT) involves a longitudinal prospective cohort to examine well-being, mental health and EC in
16–22 year olds across 12 months. Within the cohort, eligible participants are entered to either the PREVENT trial (if
selected EC scores at baseline within worst-performing quartile) or to the PROMOTE trial (if selected EC scores not
within worst-performing quartile). In both trials, participants are randomised (i) to continue with usual practice,
repeated assessments and a self-monitoring app; (ii) to additionally receive generic cognitive-behavioural therapy
self-help in app; (iii) to additionally receive personalised EC self-help in app. In total, 2142 participants aged 16 to
22 years, with no current or past history of major depression, bipolar disorder or psychosis will be recruited across
UK, Germany, Spain, and Belgium. Assessments take place at baseline (pre-randomisation), 1, 3 and 12 months post-
randomisation. Primary endpoint and outcome for PREVENT is level of depression symptoms on the Patient Health
Questionnaire-9 at 3 months; primary endpoint and outcome for PROMOTE is emotional well-being assessed on the
Warwick-Edinburgh Mental Wellbeing Scale at 3 months. Depressive symptoms, anxiety, well-being, health-related
quality of life, functioning and cost-effectiveness are secondary outcomes. Compliance, adverse events and
potentially mediating variables will be carefully monitored.
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Conclusions: The trial aims to provide a better understanding of the causal role of learning EC skills using
interventions delivered via mobile phone apps with respect to promoting well-being and preventing poor mental
health in young people. This knowledge will be used to develop and disseminate innovative evidence-based,
feasible, and effective Mobile-health public health strategies for preventing poor mental health and promoting well-
being.
Trial registration: ClinicalTrials.gov (www.clinicaltrials.org). Number of identification: NCT04148508 November 2019.
Keywords: Depression, Well-being, Personalization, Young people, Mobile-health prevention, Randomised
controlled trial, Emotional competence, Rumination
Background
There is growing global concern about the high and stead-
ily increasing rates of poor mental health in young people
and of the early onset of mental disorders such as anxiety
and depression [1]. Such poor mental health during this
key formative period severely affects the future life
chances of young people, with significant long-term im-
pact on future health, education, employment and social
outcomes [1–4]. The incidence of anxiety and depression
each markedly increase from mid-adolescence through to
young adulthood, peaking during this period [2]. As a con-
sequence, there has been a call for urgent improvement in
primary prevention of poor mental health, and for im-
provement in promotion of mental well-being [4, 5].
Although there are already evidence-based effective pri-
mary prevention interventions for common mental health
disorders including Social-Emotional Learning (SEL) pro-
grammes [6] and cognitive-behavioural approaches [7], sys-
tematic reviews suggest that effect sizes are relatively small
and there is scope to increase intervention efficacy [7–10].
Furthermore, most current evidence-based interventions
require considerable person-hours from professionals be-
cause of the involvement of a relevant workforce such as
teachers and therapists. Ideally, we need mental health pro-
motion and prevention approaches that do not require con-
siderable person-hours and that are highly scalable to a
population level, that can be delivered as a public health ap-
proach, and that can increase treatment efficacy.
To tackle these key challenges, the Assessing and En-
hancing Emotional Competence for Well-being in the
Young (ECoWeB) project innovatively integrates three
approaches: basing interventions on a model of normal
emotional functioning; personalising intervention based
on baseline scores; and the use of smartphone app deliv-
ery. First, rather than basing mental health promotion
and mental ill-health prevention on traditional clinical
disease models of psychopathology, we adopt an ap-
proach based on an established theoretical model of nor-
mal emotional functioning – the Component Process
Model of Emotion (CPM) [11–13]. This model proposes
that individuals vary in their abilities across different
areas of Emotional Competence (EC), including: (i)
accurate and functional appraisals of emotional situa-
tions and of the individual’s ability to cope with these
situations, which determines whether an individual expe-
riences the emotion appropriate to a situation (Emotion
Production); (ii) abilities to perceive and understand
emotions in themselves and others (Emotion Knowledge
and Perception); (iii) and the use of more adaptive ver-
sus less adaptive strategies to manage and regulate emo-
tions (Emotion Regulation). The model hypothesizes
that good EC functioning contributes to reduced anxiety
and depression, and improved mental well-being. Con-
siderable correlational and prospective data is consistent
with this hypothesis [14–19]. Targeting hypothesized
underlying mechanisms common across all individuals
no matter their symptomatology has the potential to en-
hance intervention efficacy and is particularly well-suited
to the promotion of well-being and prevention of poor
mental health at the population-level. As such, the ECo-
WeB project will test the efficacy of a self-help interven-
tion focused on building EC to promote well-being and
prevent poor mental health in young people.
Second, ECoWeB adopts a personalisation approach in
which individuals in the experimental intervention are of-
fered specific self-help psychoeducation, strategies and
training matched to their EC profile, on the hypothesis
that a tailored intervention will be more acceptable and ef-
ficacious than a generic intervention. This approach has
not yet been evaluated in well-being and mental health
promotion/prevention research despite recent arguments
for predictive, personalised, preventive and participatory
medicine focused on individual well-being [20].
Third, ECoWeB will investigate the delivery of the
self-help intervention through a mobile app. The use of
mobile apps (sometimes called Behavioural Intervention
Technologies, BITs) [21] has a number of potential ad-
vantages: (i) scalability–Mobile-health (m-health) tech-
nologies are highly scalable, allowing very good coverage
and reach; they are widely accessible; (ii) non-
consumable–they enable repeated use by nearly unlim-
ited people simultaneously; (iii) convenience – they can
be used anytime, anywhere; (iv) acceptability – mobile
apps are highly used by young people, with the majority
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of young people using smart phones [22]. In addition,
mobile apps can help to integrate behavioural changes
into daily life: the app is always on hand via the smart-
phone, making it well-suited for changing habits. Despite
huge increase in the numbers of m-health apps (> 10 k)
[23], only a very small minority have been based on ro-
bust science, utilised established treatment principles
and been rigorously tested with respect to safety and ef-
ficacy in robust well-powered randomised controlled tri-
als (RCTs) [24–27]. There is emerging evidence for m-
health apps as efficacious treatment interventions for
anxiety and depression [28, 29], although the average
sample size is still under 100 participants per trial arm,
and few trials have examined well-being promotion and
prevention of poor mental health specifically in young
people. To our knowledge, ECoWeB will be the first
fully powered definitive trial of an m-health app for
mental health promotion in young people.
A further issue within the field of mental health pro-
motion and prevention of poor mental health is the def-
inition of the target population of the intervention.
Population-oriented public health approaches are often
available to the general eligible population without spe-
cific targeting (i.e., a universal intervention). However,
there is some evidence that preventive interventions that
are selective and target specific higher-risk groups within
the wider eligible population, such as those with subsyn-
dromal symptoms or indicative risk factors, may be
more efficacious [8, 10]. Because this remains unresolved
and has considerable implications for future implemen-
tation, ECoWeB will include two RCTs: one selecting in-
dividuals with indicative elevated risk for future poor
mental health based on baseline EC profile (a targeted
high-risk population: ECoWeB-PREVENT), and the other
including participants without such indicative elevated
risk (a low-risk population: ECoWeB-PROMOTE), within
a single cohort multiple randomised controlled trial
(cmRCT) design [30]. In a cmRCT, individuals meeting
relevant criteria are recruited into a large-scale prospective
cohort and their outcomes are regularly monitored across
the prospective period. In addition to consenting to be
assessed over the follow-up period, participants also con-
sent to being offered additional intervention if eligible. For
each potential RCT in the cohort, information from the
cohort is used to identify all eligible participants and then
some eligible participants are randomly selected and of-
fered the additional intervention.
We stress that the two trials share the same recruit-
ment procedure, interventions, set of outcome measures
and designs and most eligibility criteria. As the funding
remit for ECoWeB was for promotion of mental well-
being and primary prevention of mental disorders, both
trials exclude those with a history of current or past
major depression or a diagnosis of bipolar disorder or
psychosis: individuals passing these criteria are eligible
for either PREVENT or PROMOTE depending on their
EC profile. The key differences between the trials are the
eligibility criteria with respect to EC profile for each trial
and as a consequence the primary outcome measure.
The ECoWeB-PREVENT trial will recruit participants
who have a hypothesized elevated risk of poor mental
health based on an EC profile in which they score in the
worst quartile on at least one EC component, such as a
greater tendency towards well-established unhelpful
emotional regulation strategies such as rumination [31–
33] or making negative appraisals [34]. For this group,
there is increased likelihood of worsening mental health
over 12 months and we choose depression symptoms
(Patient Health Questionnaire-9) as our primary out-
come as potentially the most sensitive and important
index of poor mental health. ECoWeB-PREVENT there-
fore tests whether provision of personalised digital EC
self-help can prevent the onset and increase of depres-
sion symptoms relative to generic digital CBT self-help
and the usual practice self-monitoring control.
The ECoWeB-PROMOTE trial will recruit participants
not showing elevated risk on their EC profile, that is,
relatively well and high-functioning individuals, who do
not score in the worst quartile for any of the EC compo-
nents. For this group, there is lower likelihood of wors-
ening mental health over 12 months. The sensible
primary outcome is therefore increased mental well-
being, indexed by the Warwick-Edinburgh Mental Well-
being Scale. ECoWeB-PROMOTE therefore tests
whether the provision of personalised digital EC self-
help can improve well-being relative to generic digital
CBT self-help and the usual practice self-monitoring
control. Both trials share the same secondary outcome
measures so that well-being promotion and prevention
of poor mental health can be tested in both.
Because there are many different emotional compe-
tence skills that could potentially be assessed and
trained, for initial feasibility and to test proof-of-
principle for this approach, we identified at least one
process to target with respect to each EC domain. Tar-
gets were therefore chosen that had been robustly impli-
cated in mental health and well-being, and already had
well-established validated assessment measures. These
targets were also readily adaptable and proven interven-
tions, albeit typically delivered through different media
than apps, such as web-based therapy and classroom in-
terventions. On this basis, the four target processes se-
lected were appraisal biases in achievement contexts;
interpretative biases in social contexts, each reflecting
the Emotion Production component; rumination and
worry reflecting proven dysfunctional strategies in Emo-
tion Regulation; and emotional knowledge, understand-
ing and recognition. Specifically, there are four
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components within the personalized digital EC self-help
intervention, with each individual participant receiving
their two lowest-ranked EC components based on their
EC profile.
The achievement-focused appraisal self-help compo-
nent builds on the control-value theory of achievement
emotions [35] and aims to address lack of control, lack
of value, and excessive negative value. To do so, it com-
bines three established treatment approaches: (a) attribu-
tional retraining intended to build internal and
controllable attributions for academic or work-related
outcomes to increase perceived control, building on a
video-based short intervention that has already had
benefit in college students [36–38]; (b) mindset training
to promote perceived control and growth mindsets,
found to improve academic outcomes [39, 40] and which
has been shown to reduce and prevent depression and
anxiety in young people over 9 months after a single 30-
min session [41–43]; (c) utility value self-help intended
to increase the perceived value and usefulness of aca-
demic study and employment-related tasks [44, 45], as
well as to reduce excessive concerns and fears of failure
(excessive attainment value).
The social-focused appraisal self-help component
builds on a model of youth depression which argues that
negative appraisals may mediate the harmful effects of
peer rejection on depressive symptoms [46]. Using an
established Cognitive Bias Modification of Interpreta-
tions (CBM-I) paradigm, the Ambiguous Scenarios Task
(AST), participants are trained over repeated trials to
draw more positive interpretations of ambiguous social
scenarios. Laboratory studies have demonstrated CBM-I
to show medium to large effect sizes (ESs) in modifying
negative interpretations in adults (g = 0.52 to 0.81) [47–
49] and youth (g = 0.52 to 0.70) [50]. CBM-I has been
shown to have modest benefits in reducing anxiety, and
to a lesser extent depression in adults (g = 0.23) [47, 48]
and youth with elevated symptoms (g = 0.17 to 0.34)
[50], although the true clinical benefit has been ques-
tioned in some meta-analyses [47, 51, 52].
To target the Emotion Regulation EC component,
ECoWeB adapts an existing proven intervention that tar-
gets a shift away from maladaptive worry and rumin-
ation, which are well-established risk factors for poor
mental health [32, 33] to more adaptive problem-
solving. This rumination self-help intervention builds on
proven cognitive-behavioural therapy principles and in-
cludes identifying warning signs for worry, repeated
practice to train out of unhelpful habits and build help-
ful habits, and the training of useful alternative strategies
such as being more specific, relaxation, problem-solving
and self-compassion [53]. This intervention has been
proven to be effective in reducing and preventing de-
pression and anxiety in face-to-face therapy [54–56] and
in web-based interventions for young adults [57] includ-
ing an entirely self-help variant [58].
The emotional knowledge and perception self-help
component educates and enhances EC knowledge and
perception through the provision of detailed psychoedu-
cation and adapted assessment tasks in which immediate
feedback helps users to build their skills. For example,
training feedback on the Geneva Emotion Recognition
Test which involves judging emotional expressions from
video clips (GERT) [59, 60] has been found to improve
performance on emotion recognition tests and increased
co-operation with a stranger.
Objective
The primary objective of the ECoWeB-PROMOTE trial
is to examine the efficacy of personalized digital EC self-
help relative to generic digital CBT self-help and a usual
practice self-monitoring control to improve mental well-
being at 3-month follow-up in young people with an EC
profile without elevated hypothesized risk.
The primary objective of the ECoWeB-PREVENT trial
is to examine the efficacy of personalized digital EC self-
help relative to generic digital CBT self-help and a usual
practice self-monitoring control to reduce poor mental
health indexed by self-reported depression at 3-month
follow-up in young people with an EC profile with ele-
vated hypothesized risk.
For both trials, secondary objectives are to examine
the efficacy of the interventions on secondary outcomes
concerning mental well-being and mental health and as-
sociated costs, the maintenance of these effects at 12
month follow-up and to examine potential mediators
and moderators of the beneficial effects (if any) of these
m-health interventions.
Methods
The study will be conducted and reported according to
Consolidated Standards of Reporting Trials (CONSORT)
[61, 62] and extensions for non-pharmacologic treat-
ment interventions and multi-arm parallel-group rando-
mised trials and CONSORT-EHEALTH for improving
and standardising evaluation reports of Web-based and
mobile health interventions [63].
Study design
The trial design is of a cohort multiple randomised con-
trolled trial (cmRCT) [30] involving two superiority par-
allel 3-arm randomised multicentre, multinational RCTs
(ECoWeB-PREVENT; ECoWeB-PROMOTE). The arms
are the same across both trials and all participants join
the 12 month prospective longitudinal cohort.
Within ECoWeB, all participants recruited into the pro-
spective cohort will be allocated into either the PREVENT
or PROMOTE trial, and all are then randomised into one
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of three arms. The default arm within the cohort, that is,
the control trial arm, involves completing web-based as-
sessments at baseline and at 1-, 3- and 12-month follow-
up, of well-being, mental health symptoms and EC func-
tioning, and having access to a version of the app that sup-
ports self-monitoring of the participant’s emotions, plus
any additional usual care a participant may receive exter-
nal to the trial (henceforward, “usual practice self-
monitoring control”). The active experimental arm in-
volves the receipt of personalised EC self-help strategies
within the app, in addition to the repeated measures and
self-monitoring. In addition, there is an active control arm
consisting of generic CBT self-help strategies within the
app, in addition to the repeated measures and self-
monitoring. The outcomes of participants randomly se-
lected to each of the experimental and active control arms
are compared with eligible participants randomly selected
to remain in the usual practice self-monitoring control
arm, and with each other.
There are multiple advantages to this cmRCT design.
First, it effectively combines a prospective long-term lon-
gitudinal cohort design with a randomised trial. Random
selection of some participants within each trial to add-
itional intervention is equivalent to random allocation of
all participants within each trial with respect to generat-
ing groups where all known and unknown prognostic fac-
tors are distributed evenly at baseline, enabling strong
causal inference about the causal effects of each interven-
tion. Nonetheless, retaining the default prospective cohort
group provides information as to the natural history of
well-being, emotions and mental health in this sample and
allows us to examine the trajectory of well-being and symp-
toms over time and their relationship to EC.
Second, it potentially improves the efficiency and repre-
sentativeness of sample recruitment as the study can be
open widely to eligible young people and advertised as
participating in a cohort study to learn about young peo-
ple’s emotions as well as a clinical trial. Third, because in-
dividuals consent in advance to the option of having an
intervention offered if eligible, we avoid individuals being
knowingly allocated to a “lesser” usual care condition, po-
tentially enhancing recruitment and retention.
Potential participants for either PROMOTE or PREV
ENT provide initial consent to complete screening mea-
sures to determine if they are eligible to participate in ei-
ther of the two trials (ECoWeB-PROMOTE, EC profile
not showing hypothesized elevated risk for future poor
mental health; ECoWeB-PREVENT, EC profile showing
hypothesized elevated risk for future poor mental health).
Any potential participants who are found not to be eligible
for either trial are automatically signposted to other
sources of support. Once trial eligibility has been deter-
mined and consent to participate in the trial has been ob-
tained, participants are individually selected at random (in
a 1:1:1 ratio) to be offered self-help components within a
mobile phone app (either personalised Emotional Compe-
tence self-help or general CBT self-help) or not to be con-
tacted about the offered self-help and to continue with the
app for self-monitoring only. All participants in the cohort
consent at the outset to provide data to look at the benefit
of the app self-help for well-being and mental health out-
comes. Thus the three trial arms are: (1) usual practice
self-monitoring control in which participants continue
within the cohort with repeated assessment and using an
app configured only for self-monitoring; (2) digital CBT
self-help (active treatment control) in which participants
receive the usual practice self-monitoring control and in
addition are offered generic cognitive-behavioural self-
help strategies within the app; (3) a personalised digital
EC self-help in which participants receive the usual prac-
tice self-monitoring control and in addition are offered
personalised digital self-help EC strategies within the app.
Participants allocated to personalised digital self-help EC
will receive two of four components corresponding to the
two EC domains ranked lowest in their EC profile.
Recruitment and study settings
We seek to recruit 2142 participants across four differ-
ent European countries (United Kingdom, Germany,
Spain, Belgium) with central trial sites based at the Uni-
versity of Exeter, UK; LMU Munich, Germany; Universi-
tat Jaume I, Castellon, Spain; and Gent University,
Belgium (see Figs. 1, 2 and 3).
The recruitment strategy includes online and website
advertising; email to mailing lists; newsletters and other
circulars and noticeboards within willing schools, colleges
and universities in the four countries. A social media cam-
paign will be designed and prepared to be carried out on
different social networks (e.g., Facebook, YouTube, Insta-
gram, Twitter), including advertisements in social media;
and blogs by YouTube influencers. It also includes mail-
ings to members of relevant registers (e.g. city registers);
recruitment via youth and mental health charities; bro-
chures and posters in public areas; articles in local news-
papers and press releases to the national press.
Eligibility criteria
Eligible participants for the top-level cmRCT cohort will
be: (1) young people aged 16 to 22 years old, (2) based in
the UK, Spain, Germany, or Belgium (3) having basic lit-
eracy in at least one of English, Spanish, German, or
Dutch, (4) able to provide informed consent and obtain
parental consent for those aged under 18 years old in
Germany and Belgium, and (5) having regular access to
a smart phone (android or iOS) (see Table 1).
These trials are a primary prevention trial (PREVENT)
and well-being promotion trial (PROMOTE), hence par-
ticipants will be excluded from the cmRCT cohort at
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baseline if presenting with a current episode, or if they
have a past episode of major depressive disorder (accord-
ing to psychiatric DSM-IV criteria). This is determined in
structured self-report electronic screening using the LIDA
S instrument [64]. Other exclusion criteria include: active
suicidality; any self-reported history of severe mental
health problems such as bipolar disorder and psychosis;
and currently receiving psychological therapy, counselling
or psychiatric medication including antidepressants.
Specific inclusion/exclusion criteria will determine
whether an individual is eligible for ECoWeB-PROMOTE
or ECoWeB-PREVENT: elevated hypothesized vulnerabil-
ity on EC profile based on the baseline assessment of EC
skills is an inclusion criterion for ECoWeB-PREVENT and
an exclusion criterion for ECoWeB-PROMOTE. Elevated
vulnerability for a specified EC will be defined as scoring
in the worst performing quarter on at least one measure
assessing the component, and scoring in the worst per-
forming third on the second measure for the same com-
ponent (if two measures are being used for that
component). This threshold is based on prior studies find-
ing that individuals scoring in the worst quarter on mea-
sures of EC (e.g., rumination, appraisals, interpersonal
vulnerabilities) have elevated risk for subsequent anxiety
and depression [57, 65]. The exact quartile/tertile thresh-
olds have been set following validation studies of the in-
struments in the target sample (16–22 year olds) across
the four recruiting countries.
Screening and consent procedure
Potential participants who are interested in the study are
directed to our study website, (www.mymoodcoach.com)
which provides further information, including eligibility
criteria, and a pre-screener to check age and country. If
appropriate, the website visitor is provided with the
study information sheet and an initial consent screen to
provide contact details (email; mobile phone number),
and to provide informed consent to complete the base-
line questionnaires. Individuals who are not suitable at
pre-screen (e.g., outside of age range) will automatically
Fig. 1 ECoWeB-PROMOTE and ECoWeB-PREVENT SPIRIT schedule of enrolment, interventions, and assessments
Newbold et al. BMC Psychiatry          (2020) 20:458 Page 6 of 18
Fig. 2 CONSORT flow diagram for ECoWeB-PROMOTE
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be directed to a webpage explaining why they are not
suitable for the trial. Those reporting mental health diffi-
culties will be automatically guided to webpages
providing information, guidance including to consult
with their general practitioner (or equivalent), and
weblinks and telephone numbers for help and support
Fig. 3 CONSORT flow diagram for ECoWeB-PREVENT
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specific to each country, including contact details for the
trial team.
After pre-screening, potential participants providing
their email address are automatically emailed a copy of
the information sheet, privacy policy and consent form
so they can review them prior to giving any consent.
Those potential participants who require consent from a
parent or guardian (under age 18 in Germany or
Belgium) are provided with a link to pass to their parent
or guardian, who can then also view the information
sheet and provide consent. On completion of parental
consent, participants are automatically sent a link so that
they can return to the assessment website, give their
own consent and continue with the screening. Those
not needing parental consent can consent straight away.
Once this initial consent is provided, the participant pro-
ceeds to the baseline assessment.
Those meeting eligibility criteria following the baseline
assessment are then asked to consent to take part in the
prospective cohort and cmRCT, using an electronic in-
formation sheet, consent form and electronic signature.
Once eligible participants consent to participate in the
cmRCT, they will be deterministically allocated to the
relevant trial and then randomised into one of the three
conditions by a computer system. Consenting partici-
pants will be automatically signed up to use the relevant
variant of the app via an application programming inter-
face (API). The participant’s email address is used for
app set-up.
Baseline and follow-up assessments
The baseline assessment takes place after initial elec-
tronic informed consent is provided, and consists of
web-based self-report measures to assess current and
lifetime history of depression, current well-being, symp-
toms of anxiety and depression, social and work func-
tioning, health-related quality of life, stressful events,
and EC skills in each of the four study languages
(English, German, Spanish, Dutch) (see outcome mea-
sures and Table 2). All of the questionnaires have been
validated in all four languages. The Lifetime Depression
Assessment Self-report questionnaire (LIDAS) [64] is
used to assess lifetime major depression (MDD) diagno-
sis according to DSM criteria, and is largely based on
the widely used Composite International Diagnostic
Interview (CIDI). It has been proven to be effective for
determining history of depression through self-report in
an online digital format, matching the needs for the
current study [64]. It consists of a conditional sequence
of pre-programmed questions assessing all the diagnostic
criteria for depression, with logic cut-outs so that subse-
quent questions are determined by prior questions,
keeping the assessment brief.
All participants are entered into the prospective cohort
and followed up electronically at 1, 3 and 12months
post-randomisation. At each follow-up point, partici-
pants will be automatically sent emails with links to
enter their data into the assessment website. Each as-
sessment point will involve an automated weekly follow-
up and then email, text and telephone follow-ups by re-
searchers to participants who haven’t yet completed the
website assessment at 3 months and 12months. Figure 1
and Table 2 give an overview of all measurements. Site
researchers will be blind to treatment allocation, but will
be available to participants to follow up risk and answer
technical queries. Participants receive honorariums for
the completion of each follow-up assessment.
Randomisation, intervention delivery and masking
Participants will be randomised (in a 1:1:1 ratio) to the
three intervention arms within each trial. Randomisation
will be conducted automatically by means of a custom-
built secure web service created and managed by the
Exeter Clinical Trials Unit (ExeCTU), which interfaces
with the trial database. To promote balance across key
participant characteristics across intervention arms, ran-
domisation will be minimised according to recruitment
country (UK, Spain, Germany, Belgium), age (under 18
years old versus 18 years or older), and gender (male, fe-
male, both, neither). The minimisation algorithm will re-
tain a stochastic element and the first 50 participants
(PREVENT) and 150 (PROMOTE) will be allocated to
their intervention arm by simple random allocation.
All of the online recruitment and randomisation will
be automated and independent of trial researchers. The
ExeCTU database will automatically send Monsenso (the
app developer) the email address of the participant, their
language and the version of the app that the participant
is randomised to (control, active control or personalised
EC version), enabling the participant to be set up with
an account on the app. The online randomisation pro-
cedure will generate a unique trial identification code
Table 1 Inclusion and exclusion criteria
Inclusion criteria
16 to 22 years old
Living in UK, Spain, Germany, Belgium
Fluent in at least one of English, Spanish, German, Dutch (Flemish)
Able to provide informed consent or parents willing to provide
consent if under 18 years of age in Germany and Belgium
Regular access to Android or iOS smartphone
Exclusion criteria
Current or Lifetime diagnosis of Major depressive Disorder (DSM-IV
criteria, LIDAS self-report).
Current use of antidepressant drugs or psychological interventions
History of psychosis, bipolar disorder, substance dependence or other
severe psychiatric disorder or current suicidality
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that is linked to the account on the app. All assessments
will be routinely collected online using the assessment
website following automated reminders, without the in-
volvement of researchers. Site researchers will be blind
to treatment allocation. Site researchers will prompt all
participants to complete follow ups by phone, text and
email if they do not respond to the automated re-
minders. Any unblinding in contact with a site re-
searcher would be logged as protocol violations and only
a researcher that remained blind will be able to prompt
future follow-up from that participant.
Interventions
Usual practice self-monitoring control
This control is carrying on in the prospective cohort,
that is, usual practice plus the default basic version of
the app featuring self-monitoring and the regular assess-
ments within the cohort. Self-monitoring will include
daily mood ratings and an ecological momentary assess-
ment option (MoodTracker) for more detailed analysis
of mood, activity and situational context. This self-
monitoring is intended to help young people learn more
about their emotional experiences and what influences
them. Usual practice, as received by the young person
outside of the trial, may include no provision of inter-
vention, local provision of intervention, support from
their GP/family doctor, local health services or youth
services, or provision of intervention within their educa-
tional institution (e.g., well-being service at university;
support and welfare staff at school). The nature of usual
practice will be monitored and assessed by question-
naires at each follow-up assessment, determining what
treatment and services participants have received since
the last assessment.
Non-personalised digital self-help using generic CBT
principles (active control group)
The active control will be a non-personalised digital self-
help based on generic principles derived from cognitive
behaviour therapy (CBT) for promoting mental well-
Table 2 Measurements and Endpoints
Follow-up
(months)
Web Assessment Baseline 1 3 12




Socio-demographics Age, sex, education, parental occupational status, country
of birth, ethnicity
✓
Well-being WEMWBS questionnaire; primary outcome for PROMOTE ✓ ✓ ✓ ✓
LIDAS Self-report assessment of current and past MDE according to
the definitions/ criteria of DSM-IV
✓ ✓ ✓
Depression PHQ-9 questionnaire; primary outcome for PREVENT ✓ ✓ ✓ ✓
Anxiety GAD-7 questionnaire; secondary outcome ✓ ✓ ✓ ✓
General functioning Work and social adjustment (WSAS) questionnaire ✓ ✓ ✓ ✓
Quality of Life EQ 5D-3L measure ✓ ✓ ✓
Estimate of health costs Adapted AD-SUS ✓ ✓ ✓
Stress and adverse events Adverse Events Questionnaire, designed to assess common
stressors in young people
✓ ✓
Emotional Competence – Emotional Regulation Rumination using brooding subscalea of Ruminative Response
Scale of Response Styles Questionnaire; worry, using short Penn
State Worry Questionnairea
✓ ✓ ✓ ✓
Emotional Competence – Emotional Knowledge
and Perception
Abbreviated Geneva Emotion Recognition Test (GERT)a –
performance measure of ability to recognise emotions from
non-verbal cues; Components of Emotional Understanding
Task (CEUT)a.
✓ ✓ ✓ ✓
Emotional Competence – Production (Social Appraisal) Rejection Sensitivity Questionnairea to assess tendency for negative
expectations of social situations
✓ ✓ ✓ ✓
Emotional Competence – Production
(Achievement Appraisal)
Abbreviated Control Belief Scale; abbreviated; abbreviated
Perceived Academic Control scalea; abbreviated Growth
Mindset Scale and Academic Value scalesa; abbreviated
abbreviated Achievement Emotions Questionnaire
✓ ✓ ✓ ✓
Note: Measures in italics are those used for selecting to ECoWeB-PREVENT vs ECoWeB-PROMOTE; measures indicated with a are those used in personalising
intervention in EC self-help arm
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being and for preventing poor mental health. This self-
help app will use well-established generic cognitive-
behavioural principles, including tips, advice, strategies
and psychoeducation including on behavioural activation
to increase positive activities, problem-solving and spot-
ting and challenging negative thoughts, proven in RCTs
to reduce symptoms of depression and anxiety and to
promote well-being in young adults via online delivery
[7, 8]. It will be delivered via an app using the same fea-
tures, menu and structure as the personalised EC self-
help to make the interventions as similar and as consist-
ent in delivery as possible and to enable the interven-
tions to be matched for delivery and format.
Personalised digital EC self-help (experimental intervention
group)
The experimental arm is Emotional Competence (EC)
self-help incorporating mobile smartphone application
(app) delivery. As described earlier, there are four poten-
tial components focusing on different EC component
processes: (i) improving accurate and functional emotion
production via enhancing appraisals of achievement situ-
ations emphasizing increased perceived control and real-
istic perceived value (Achievement Appraisal); (ii)
improving accurate and functional emotion production
via training positive interpretations of ambiguous social
events (Social Appraisal); (ii) improving emotional regu-
lation by reducing maladaptive worry and rumination
and replacing with constructive alternatives and
problem-solving (Rumination); and (iv) enhancing emo-
tional knowledge and perception through psychoeduca-
tion and learning tasks (Emotion Knowledge). The
personalised digital EC self-help provides psychoeduca-
tion, tips, advice, exercises and training for each individ-
ual on the two EC components deemed to be most
appropriate based on the baseline assessment. The app
will include text, pictures, audio-recordings, animations,
audio-exercises to practice (e.g., self-compassion), ques-
tionnaires with tailored feedback, quizzes, and gamifica-
tion (e.g., badges, rewards, feedback). It will feature a
menu structure including a dashboard to monitor notifi-
cations and progress, an explore function to graph the
self-monitoring responses made by the participant, Chal-
lenges that provide learning exercises, and Tools that are
brief strategies that young people can use in the moment
when they need them. Within the app to support enhan-
cing emotion knowledge, an innovative feature will be
explored involving voluntarily provided audio-recordings
being used to provide estimated feedback on perceived
emotional arousal and dominance dimensions by ma-
chine learning techniques.
The app will be designed for iOS and Android use. All
versions of the EC personalized self-help app will in-
clude the default self-monitoring features (including a
regular daily mood rating and ecological momentary as-
sessment) and gamification. To increase adherence on
the app, completion of self-monitoring, Challenges
(learning exercises) and Tools (practice of strategies) are
each gamified, with badges earnt for progress on each
and with electronic vouchers earnt when groups of
badges are completed.
In recognition that behavioural intervention technolo-
gies rapidly evolve over time and that the technological
instantiation can require debugging, updates, and en-
hancements of user interface, we will explicitly adopt the
Trial of Intervention Principles approach [66]. This ap-
proach distinguishes between the underlying principles
and behavioural strategies of a psychological interven-
tion (e.g., goal setting, habit change), which need to re-
main unchanged to maintain trial integrity and
robustness, and the specific technological instantiation
of these principles (e.g., specific user flow, user experi-
ence and design), which can potentially change without
compromising trial integrity. This provides the possibil-
ity to update the app – to correct bugs, upgrade systems
and user interface – as long as any changes remain con-
sistent with our a priori operationalisation of treatment
principles and subject to independent agreement from
our independent External Advisory Board.
Intervention adherence
The use of the app will be assessed and recorded includ-
ing number of times the app is used and the number of
badges received in the gamification system. A minimum
intervention dose for the EC and CBT self-help arms
(treatment compliance) will be defined a priori, based on
the principle that users will benefit from learning new
ideas (completing Challenges) and practising new skills
(completing Tools). All participants in the usual practice
self-monitoring control are defined as receiving the
minimum intervention dose.
Outcomes
Outcomes will be assessed at baseline (pre-randomisa-
tion) and 1, 3, and 12 months post-randomisation.
Primary outcome
The primary outcome measure for ECoWeB-PROMOTE
will be the 14-item Warwick-Edinburgh Mental Well
Being Scale (WEMWBS) [67, 68], a leading validated
self-reported index of well-being with excellent psycho-
metric properties, at 3-month follow-up (the primary
endpoint).
The primary outcome measure for ECoWeB-PREV
ENT will be the state depression score of the partici-
pants on the Patient Health Questionnaire-9 (PHQ-9)
[69], a well-validated measure of depression at 3-month
follow-up (the primary endpoint).
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Secondary outcomes
Secondary outcomes include: PHQ-9 [69] (for ECoWeB-
PROMOTE), WEMWBS [68] (for ECoWeB-PREVENT).
The Generalized Anxiety Disorder-7 (GAD-7) question-
naire will be used to assess anxiety symptoms [70]. The
Work and Social Adjustment Scale (WSAS) [71] will be
used to measure functioning with respect to work/edu-
cation, home management, social leisure, private leisure
and close relationships each rated from 0 not at all im-
paired to 8 severely impaired. Health-related quality of life
will be assessed by the EuroQol instrument EQ-5D-3L
[72]. The Adult Service Use Schedule (ADSUS-adapted)
[73, 74] will be adapted for adolescents and young adults
and is a well-established measure within the health eco-
nomics field used to index relevant health and social care
costs for trial participants. The Adverse Events Question-
naire is a brief measure designed to assess stressful events
in young people across the domains of academic study, re-
lationships, other bad experiences, hassles, which is
proven to predict subsequent depression [75].
Emotional competence skills
Different Emotional Competence skills are assessed
through a battery of well-validated questionnaires and
tasks, adapted and shortened for web-use: a validation
study across all four countries determined shortened ver-
sions that maintained good psychometric properties. EC
skills are assessed to allocate individuals to ECoWeB-
PROMOTE or ECoWeB-PREVENT trials, to inform per-
sonalisation of treatment where applicable, as a manipula-
tion check that interventions influence the targeted EC,
and as potential mediators of intervention effect.
Emotion Knowledge and Perception: a brief version of
the Components of Emotional Understanding Task
(CEUT) [76] is used to assess understanding of all five
emotion components of the Componential Emotion Ap-
proach (appraisals, action tendencies, bodily reactions,
expression, subjective feelings). Participants read a series
of emotion eliciting situations that describe potential
emotional components, which the participant then rates
for likelihood. The CEUT has good reliability and con-
vergent validity.
The brief version of the Geneva Emotion Recognition
Test (GERT-S) [77] is used to assess emotion percep-
tion: it is a 20-item performance-based emotion recogni-
tion test in which participants view short video clips of
actors expressing 14 different emotions and then report
which emotion had been expressed.
Emotion Production: To assess different components
of appraisals, we will use (a) a shortened Emotional Dis-
position (EmoDis) tool [78] which asks participants to
imagine experiencing four standardized emotional sce-
narios and rate their appraisals on three dimensions and
the strength of three emotions; (b) a 4-item version of
the Control Belief Scale which measures beliefs about
one’s control, power and personal efficacy [79]; (c) ab-
breviated versions of the Perceived Academic Control
scale [80]; Growth Mindset Scale [81] and Academic
Value scales [82] to assess appraisals in achievement set-
tings and intrinsic, utility, and attainment value. We will
also use an abbreviated Achievement Emotions Ques-
tionnaire [83] to assess common emotions (enjoyment,
anxiety, hopelessness, boredom) in different achievement
contexts (school, university, work); the Rejection Sensi-
tivity Questionnaire (ARSQ) [84] to assess concerns and
expectations of the likelihood of rejection versus accept-
ance in social scenarios.
Emotion Regulation: Indices of emotion regulation will
focus on repetitive negative thought in the form of worry
and rumination: (a) the 5-item brooding subscale of the
Ruminative Response Scale [85], a well-established
measure of unhelpful rumination, which predicts subse-
quent depression; (b) the Penn State Worry Question-
naire -Abbreviated (PSWQ-A) [86], a well-validated 8-
item measure of trait tendency towards worry.
The following descriptive variables will be assessed
only at baseline: country of residence, age, gender, edu-
cational level, family’s occupational status, country of
birth.
Sample size
Because ECoWeB-PROMOTE and ECoWeB-PREVENT
have different primary outcomes, the sample size for
each trial was calculated using the respective primary
outcome based on a minimum clinically important dif-
ference (MCID). The primary outcome for ECoWeB-
PROMOTE is WEMWBS, which has a recommended
MCID of 3.0 units [87]. This is based on observed smal-
lest differences in prior studies and the lowest value
greater than the observed standard error of measure-
ment [88]. It was also the observed difference between a
minimal self-help online CBT treatment and waiting list
control at the 12-week endpoint for adults [89]. A stand-
ard deviation (SD) of 11.3 units is the most conservative
estimate [88]. Using these values, with 90% power and a
statistical significance threshold of 0.05, the sample size
required for a 2-arm comparison would be 300 partici-
pants per arm. Accounting for 40% attrition at 3-month
follow-up (the primary follow-up timepoint), a total of
500 participants per arm are required. Therefore, across
the three arms of the trial, 1500 participants are
required.
The primary outcome for ECoWeB-PREVENT is
PHQ-9, which has an established MCID of 2.59 and SD
of 5.4 [90]. Using the same power requirements as for
ECoWeB-PROMOTE, the sample size required per arm
is 93 participants. Accounting for 40% attrition at 3-
month follow-up, 155 participants per arm are required,
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producing a total of 465 participants across the three
arms.
A top level cohort, comprising young adults eligible
for either trial, and assuming 70% eligible for ECoWeB-
PROMOTE versus 30% for ECoWeB-PREVENT, will re-
quire 2142 participants (i.e., to achieve 1500 participants
for PROMOTE, estimate to recruit 642 participants for
PREVENT). For all participants recruited within the first
2 months from start of recruitment, we will calculate loss
to 3-month follow-up and should it exceed 40%, we will
re-adjust the sample size accordingly. In the event of loss
to follow-up being less than 40%, the sample size will
not be reduced.
Statistical analysis plan
The primary analyses will be intention-to-treat (ITT)
analyses [91] (i.e. all participants will be included in the
analyses according to their randomised allocation) and
based on complete case outcome data. The primary in-
ferential analyses will compare across trial arms for the
primary and continuous secondary outcomes at 3-
months follow up using linear or logistic regression
models with adjustment for baseline score, age (as a con-
tinuous variable rather than the dichotomised minimisa-
tion variable), country, and any other participant
characteristics observed at baseline to be unbalanced
across treatment arms.
A number of secondary analyses will be undertaken:
(1) Complier Average Causal Effect (CACE) analysis
[92, 93] to provide an estimate of a treatment effect
accounting for pre-specified per protocol adherence
and compliance with the treatment, whilst retaining
the benefits of randomisation. Such models will be
performed for the continuous primary and second-
ary outcomes at 3- and 12-month follow-up using
observed data only, and will include the covariates
adjusted for in the linear regression models.
(2) Repeated measures analyses (using a mixed effects
linear regression model with a random effect on
participant) will be used to compare for primary and
secondary outcomes across all follow up points of 1,
3 and 12months, including data from participants
with observed data for at least one of the three
follow-up timepoints. Analyses will be performed to
compare both active interventions with usual care,
and to compare the personalised active intervention
with the standard active intervention. A fixed effect
interaction between timepoint and trial arm will be
used to evaluate differential treatment effects across
timepoints. Adjustments for baseline covariates will
be made as for the primary analysis regression
models; baseline score will be included as a covariate.
Binary outcome measures will be analysed using
logistic regression models with adjustments for co-
variates as above.
(3) The pattern of missing outcomes will be examined
and multiple imputation will be used to impute
primary and secondary continuous outcomes.
Imputation models will be informed by treatment
arm, baseline scores, other covariates to be included
in the model, and other baseline characteristics
found to predict outcome or propensity for
missingness (logistic regression models will be used
to investigate the associations between baseline
characteristics and missingness). Results of imputed
models will be compared to primary analysis
complete case ITT models.
(4) Mediation analyses will be undertaken to gain
insight into mechanisms that could explain the
potential effect of the interventions on primary
outcomes. We will use modern causal inference
methods using structural equation modelling or
parametric regression models to assess mediation
effects [94] including through changes in the EC
variables. In addition, we will investigate potential
moderation of the interventions by site, age, and
sex.
Analyses will be undertaken by a statistician blinded to
group allocation and using Stata v.15.
Health economic analysis plan
The economic analyses will use a cost-consequence ap-
proach [95] for each country in the study, using a 12
month time horizon. Health and social care utilisation
will be identified and collected using an adapted version
of the Adult Service Use Schedule (AD-SUS) question-
naire, which quantifies the use of healthcare resources,
use of medication and employment and time off work
over the trial including follow up [74]. Adaptation will
include time away from school or college together with
changes to the wording to ensure relevance across the
four countries. Unit costs of health and social care will
be taken from appropriate national publications to re-
flect differences in costs between countries. Productivity
losses will be valued using the human capital approach
[96]. Wage rates for each country will be derived from
European sources such as Eurostat. Outcomes will be
assessed using the EQ-5D-3L [72], which will be con-
verted to utility values using the EuroQoL general popu-
lation tariff values for each country. Analyses will be on
the intention-to-treat basis, and will be based on ob-
served data only. Within country analyses of the differ-
ences between the trial arms will be undertaken.
Although the distribution of costs is commonly skewed
in populations of this kind, analyses will compare mean
costs between groups using standard parametric
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regression models adjusted for minimisation variables
and baseline costs. The robustness of the parametric
tests will be confirmed using bias-corrected, non-
parametric bootstrapping [97, 98]. As with primary and
secondary outcomes, between group differences in costs
and EQ-5D-3L will be presented as means and 95% CIs
using Stata v15. Given the differences in cost structures
(health and social care, and wage rates) and differences
in the population tariffs between countries, no formal
analyses of differences between costs and utility values
between countries will be undertaken. However, the dif-
ferences between the number and type of resource use
and days away from education or work and employment
will be examined.
Qualitative analyses
During the cmRCT, implementation science approaches
will examine the feasibility, fidelity, and acceptability of
the interventions and examine the sustainability of up-
take, pathways to increased uptake and usage, and po-
tential barriers and obstacles to implementation. This
process evaluation will identify enablers and barriers to
the EC approach and conditions for implementation.
The Consolidated Framework for Implementation Re-
search (CFIR) [99] model will be used to examine the
key domains of relevance and mediators and moderators
for the implementation of the EC and CBT self-help
apps. We will use a mixed methods approach, with
quantitative and qualitative methods [100] combined
with pragmatic measures, consistent with the MRC
framework for developing and evaluating complex inter-
ventions [101, 102] and with constructs incorporating
Theory of Change approaches [103]. Thirty to forty par-
ticipants will be interviewed immediately post-
intervention and at their 3 month follow-up, matching
to their quantitative data collection points to reduce
Hawthorne effects and to facilitate data integration at
the analysis stage. We will ask about the following im-
plementation outcomes for personalized EC and control
interventions: Feasibility (e.g., how easy/difficult is it for
young people to do this intervention; do they complete
it?); Fidelity (e.g. how consistently is it experienced
across the different settings?); Penetration (e.g., how well
has it reached those young people for whom it has been
primarily designed?); Acceptability (e.g., do young people
like to use it? Is it more acceptable in certain cultural
groups?); Sustainability (e.g., How well can it continue to
be made available to relevant young people?); Cost (e.g.,
what is the intervention’s potential economic impact on
downstream health service use, educational attainment
and employment). Exact subgroups will be informed by
the development phase and early app usage statistics
during the trials.
Organization, quality assurance and data management
Research data will be automatically collected in a pseu-
donymised manner through an electronic data capture
system delivered from the website through to the central
study database. In the first instance all participants will
be directed to the website to provide their data. Ques-
tionnaires from respondents who prefer a paper version
or who respond to follow-ups by telephone will be en-
tered into the system by a site researcher research assist-
ant and this variation in data collection method will be
recorded. All data will be kept securely and confiden-
tially and only accessed by specified researchers in each
trial site. The central data-management team will use
de-identified backups for the monitoring of the overall
progress and data quality. Ultimately, a comprehensive
de-identified dataset will be produced that includes data
from all four research sites.
Trial status
The Trial was registered in ClinicalTrials.gov. Number
of identification: NCT04148508 (www.clinicaltrials.org).
November 2019. Recruitment will commence in Septem-
ber 2020.
Discussion
In recent years, improving the mental health of young
people has been identified as a global health priority [4,
104]. Improving the mental health of young people in-
cludes both the prevention of poor mental health, such
as the onset of anxiety and depression, and the promo-
tion of increased well-being. Effective approaches to im-
prove prevention and well-being promotion need to be
widely accessible and highly scalable so that they can be
reach large numbers of young people. One potential ap-
proach to delivering a scalable intervention is through
the use of mobile apps (m-health) as the majority of
young people regularly use mobile devices.
Whilst there is emergent evidence that mental health
apps can be beneficial, to date the majority of apps avail-
able have not been tested in controlled trials and those
that have been tested have been examined in relatively
small samples. Large-scale intervention studies to estab-
lish the true impact of m-health apps on the promotion
of well-being and the prevention of poor mental health
are therefore needed specific to this age group.
The ECoWeB trial is an important contribution to this
field by aiming to deliver one of the largest randomized
controlled trials (n = 2142) to specifically examine the ef-
ficacy of m-health apps on the promotion of well-being
and the prevention of poor mental health in 16–22 year
olds across four European countries. More specifically,
the study evaluates the efficacy of two different m-health
strategies – a personalised self-help EC training smart-
phone app versus a generic CBT self-help smartphone
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app. As such, the ECoWeB trial will contribute to our
knowledge of the efficacy and acceptability of different
self-help mobile apps to improve mental health in young
people. Moreover, ECoWeB is one of the first mental
health trials to incorporate a personalization element as
a test of whether a personalised approach can enhance
outcomes relative to established generic interventions. In
the personalised self-help EC training condition, partici-
pants will receive components matched to their respect-
ive abilities in emotional competence skills, to test if
such matching improves treatment efficacy and usage
compared to a standard non-matched intervention.
Because the trial is conducted across four distinct
European states (UK, Germany, Spain, Belgium), it is en-
visaged that any findings could be generalised more
broadly for young people across Europe and potentially
around the world. By including repeated measurement
of EC skills, mental well-being, and symptoms of anxiety
and depression across the longitudinal cohort of the
study, we also hope to learn more about the relative
interaction of EC skills, well-being and mental health.
For example, the trial design will enable us to determine
which m-health strategies do improve EC skills, and
whether this improvement in EC skills in turn predicts
improvements in well-being. We hope that the lessons
gained from the trial will enable the further development
and enhancement of evidence-based m-health self-help
strategies to promote well-being and prevent poor men-
tal health in young people, and thereby contribute to ad-
dressing the priority of improving mental health in
young people.
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